These symptoms had started around 2 weeks after his second AZD1222 vaccination. Endocrinological tests revealed central diabetes insipidus and mild prolactinemia, but no basal or dynamic ...
AZD1222, developed by the University of Oxford and licenced to AstraZeneca, was among the first vaccines created to protect against COVID-19. A non -replicating viral vector vaccine which was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback